New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
09:07 EDTOXGNOxigene presents encouraging OXi4503 preclinical and clinical data
Oxigene announced that investigators at the University of Florida presented encouraging clinical data using Oxigene's vascular disrupting agent, or VDA, OXi4503, in patients with acute myelogenous leukemia, or AML, at the annual meeting of the American Society of Hematology in Atlanta, Georgia. The data showed responses and a manageable safety profile in this first-in-man trial of a VDA in AML. Overall response was 2/5, or 40%, with 1 patient achieving a marrow complete remission, or mCR, and 1 patient achieving a partial remission. The median number of cycles was 1, in a range of 1-6. Three of 5 subjects discontinued the study due to AML progression and one due to pneumonia. One patient with AML treated with 5 mg/m2 OXi4503 has received 6 months of treatment and continues to receive weekly infusions.
News For OXGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 20, 2015
08:02 EDTOXGNOXiGENE announces $10M at-the-market registered direct offering
OXiGENE announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of $10< of registered shares of OXiGENE common stock in an at-the-market direct offering at a price of $1.7125 per share. For each share of common stock purchased, investors will receive a warrant to purchase one half of a share of common stock at an exercise price of $1.7125 per share, which are exercisable immediately and expire five years from the date of issuance. H.C. Wainwright & Co. acted as the exclusive placement agent in connection with this offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use